Tema Etfs LLC Trims Holdings in Intellia Therapeutics, Inc. $NTLA

Key Points

• Tema Etfs LLC significantly reduced its holdings in Intellia Therapeutics by 82.1%, ending up with only 26,537 shares valued at $189,000 after selling 121,630 shares in the first quarter.
• Institutional investors showed varied activity, with Cambridge Investment Research Advisors increasing their stake in Intellia by 51.7%, while Deutsche Bank AG raised theirs by 12.1%. Meanwhile, 88.77% of the stock remains owned by hedge funds and other institutions.
• Recent analyst upgrades led to mixed ratings and price target reductions for NTLA, with Wells Fargo issuing an "overweight" rating at a $45.00 price target, while Royal Bank of Canada reduced its target from $25.00 to $21.00.

Tema Etfs LLC decreased its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 82.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,537 shares of the company's stock after selling 121,630 shares during the period. Tema Etfs LLC's holdings in Intellia Therapeutics were worth $189,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. ARK Investment Management LLC increased its position in Intellia Therapeutics by 3.8% during the 1st quarter. ARK Investment Management LLC now owns 13,011,015 shares of the company's stock worth $92,508,000 after purchasing an additional 474,629 shares during the period. Vanguard Group Inc. grew its holdings in shares of Intellia Therapeutics by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock worth $76,447,000 after acquiring an additional 561,978 shares during the period. Two Sigma Advisers LP grew its holdings in shares of Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company's stock worth $23,300,000 after acquiring an additional 970,700 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Intellia Therapeutics by 36.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,976,212 shares of the company's stock worth $23,042,000 after acquiring an additional 528,962 shares during the period. Finally, Two Sigma Investments LP grew its holdings in shares of Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company's stock worth $21,498,000 after acquiring an additional 863,363 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Insiders Place Their Bets

In related news, EVP Edward J. Dulac III sold 7,462 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total value of $104,617.24. Following the transaction, the executive vice president directly owned 106,062 shares of the company's stock, valued at approximately $1,486,989.24. This trade represents a 6.57% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director William J. Chase bought 100,000 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was purchased at an average cost of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the transaction, the director directly owned 134,693 shares in the company, valued at approximately $1,350,970.79. This trade represents a 288.24% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have sold 12,534 shares of company stock worth $153,837. Corporate insiders own 3.10% of the company's stock.

Analyst Ratings Changes

A number of research firms recently weighed in on NTLA. Royal Bank Of Canada lowered their price target on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Guggenheim restated a "buy" rating and issued a $14.00 price target on shares of Intellia Therapeutics in a report on Wednesday, August 13th. Chardan Capital reduced their target price on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Wedbush reaffirmed a "neutral" rating and issued a $7.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 16th. Finally, HC Wainwright reduced their target price on Intellia Therapeutics from $30.00 to $25.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Twelve equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Intellia Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $29.05.

Intellia Therapeutics Trading Up 0.4%

Shares of Intellia Therapeutics stock traded up $0.05 during trading hours on Tuesday, reaching $11.41. 2,908,996 shares of the company's stock were exchanged, compared to its average volume of 4,078,769. Intellia Therapeutics, Inc. has a 52-week low of $5.90 and a 52-week high of $23.76. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -2.43 and a beta of 2.28. The company has a fifty day moving average of $11.32 and a 200-day moving average of $9.58.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping analysts' consensus estimates of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The company had revenue of $14.25 million for the quarter, compared to analyst estimates of $12.26 million. During the same quarter in the prior year, the company posted ($1.52) EPS. The business's revenue for the quarter was up 104.3% compared to the same quarter last year. On average, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.